UPDATE: SVB Leerink On Vertex Pharmaceuticals Downgrade: Firm Sees Biopharma Multiple Compression Occurring With Expectations Of >$10B To Supplement Internal Research Efforts & Portfolio; Projects FY1 Multiple Down Another 25% Over Coming Year